Search research articles
Contact Us
Filters
Showing results (201-210 of 243) with videos related to
Page
of 25
Sort By:
Clinical and Translational Radiation Oncology
|
August 18, 2025
Reirradiation of recurrent glioblastoma: Results from a single-center retrospective cohort study
Cas S Dejonckheere, Thomas Zeyen, Cathrina Duffy, et al.
Journal of Neuro-Oncology
|
September 20, 2023
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
Thomas Zeyen, Daniel Paech, Johannes Weller, et al.
Neuro-Oncology
|
February 18, 2020
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma
Antje Wick, Tobias Kessler, Michael Platten, et al.
Neuro-Oncology Advances
|
January 7, 2021
Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling
Marijke B Coomans, Linda Dirven, Neil K Aaronson, et al.
Journal of Neuro-Oncology
|
November 3, 2023
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
Thomas Zeyen, Daniel Paech, Johannes Weller, et al.
Neurological Research and Practice
|
October 18, 2023
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
Niklas Grassl, Katharina Sahm, Heike Süße, et al.
Journal of Neuro-Oncology
|
May 6, 2020
Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study
Linda Dirven, Ralf Luerding, Dagmar Beier, et al.
Nature Medicine
|
September 22, 2023
A H3K27M-targeted vaccine in adults with diffuse midline glioma
Niklas Grassl, Isabel Poschke, Katharina Lindner, et al.
Neuro-Oncology Advances
|
October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma
Lazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.
Journal of Cancer Research and Clinical Oncology
|
May 30, 2018
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial
Christina Schaub, Sied Kebir, Nina Junold, et al.
Page
of 25
Search research articles
Search
Showing results (201-210 of 243) with videos related to
Sort By:
Page
of 25
Clinical and Translational Radiation Oncology
|
August 18, 2025
Reirradiation of recurrent glioblastoma: Results from a single-center retrospective cohort study
Cas S Dejonckheere, Thomas Zeyen, Cathrina Duffy, et al.
Journal of Neuro-Oncology
|
September 20, 2023
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
Thomas Zeyen, Daniel Paech, Johannes Weller, et al.
Neuro-Oncology
|
February 18, 2020
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma
Antje Wick, Tobias Kessler, Michael Platten, et al.
Neuro-Oncology Advances
|
January 7, 2021
Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling
Marijke B Coomans, Linda Dirven, Neil K Aaronson, et al.
Journal of Neuro-Oncology
|
November 3, 2023
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
Thomas Zeyen, Daniel Paech, Johannes Weller, et al.
Neurological Research and Practice
|
October 18, 2023
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
Niklas Grassl, Katharina Sahm, Heike Süße, et al.
Journal of Neuro-Oncology
|
May 6, 2020
Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study
Linda Dirven, Ralf Luerding, Dagmar Beier, et al.
Nature Medicine
|
September 22, 2023
A H3K27M-targeted vaccine in adults with diffuse midline glioma
Niklas Grassl, Isabel Poschke, Katharina Lindner, et al.
Neuro-Oncology Advances
|
October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma
Lazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.
Journal of Cancer Research and Clinical Oncology
|
May 30, 2018
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial
Christina Schaub, Sied Kebir, Nina Junold, et al.
Page
of 25